Menu
GWAS Study

Mutations in BRIP1 confer high risk of ovarian cancer.

Rafnar T, Gudbjartsson DF, Sulem P et al.

21964575 PubMed ID
GWAS Study Type
42247 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RT
Rafnar T
GD
Gudbjartsson DF
SP
Sulem P
JA
Jonasdottir A
SA
Sigurdsson A
JA
Jonasdottir A
BS
Besenbacher S
LP
Lundin P
SS
Stacey SN
GJ
Gudmundsson J
MO
Magnusson OT
LR
le Roux L
OG
Orlygsdottir G
HH
Helgadottir HT
JH
Johannsdottir H
GA
Gylfason A
TL
Tryggvadottir L
JJ
Jonasson JG
DJ
de Juan A
OE
Ortega E
RJ
Ramon-Cajal JM
GM
García-Prats MD
MC
Mayordomo C
PA
Panadero A
RF
Rivera F
AK
Aben KK
VA
van Altena AM
ML
Massuger LF
AM
Aavikko M
KP
Kujala PM
SS
Staff S
AL
Aaltonen LA
OK
Olafsdottir K
BJ
Bjornsson J
KA
Kong A
SA
Salvarsdottir A
SH
Saemundsson H
OK
Olafsson K
BK
Benediktsdottir KR
GJ
Gulcher J
MG
Masson G
KL
Kiemeney LA
MJ
Mayordomo JI
TU
Thorsteinsdottir U
SK
Stefansson K
Chapter II

Abstract

Summary of the research findings

Ovarian cancer causes more deaths than any other gynecologic malignancy in developed countries. Sixteen million sequence variants, identified through whole-genome sequencing of 457 Icelanders, were imputed to 41,675 Icelanders genotyped using SNP chips, as well as to their relatives. Sequence variants were tested for association with ovarian cancer (N of affected individuals = 656). We discovered a rare (0.41% allelic frequency) frameshift mutation, c.2040_2041insTT, in the BRIP1 (FANCJ) gene that confers an increase in ovarian cancer risk (odds ratio (OR) = 8.13, P = 2.8 × 10(-14)). The mutation was also associated with increased risk of cancer in general and reduced lifespan by 3.6 years. In a Spanish population, another frameshift mutation in BRIP1, c.1702_1703del, was seen in 2 out of 144 subjects with ovarian cancer and 1 out of 1,780 control subjects (P = 0.016). This allele was also associated with breast cancer (seen in 6/927 cases; P = 0.0079). Ovarian tumors from heterozygous carriers of the Icelandic mutation show loss of the wild-type allele, indicating that BRIP1 behaves like a classical tumor suppressor gene in ovarian cancer.

640 European ancestry cases, 41,607 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

42247
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Iceland
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.